BioSpace News Archive

Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer

Findings Demonstrate Strong Performance of GRAIL’s Multi-Cancer Early Detection Blood Test in Patients with Suspicion of Cancer

Verastem, Inc. announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors.

EOS imaging, a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, was notified by Alphatec Holdings, Inc.

BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin significantly increased survival in pneumonia due to severe influenza.

Dr. Reddy’s Laboratories Ltd. announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® Tablets, approved by the U.S. Food and Drug Administration.

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced data related to flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule being evaluated in patients with refractory acute myeloid leukemia.

Alligator Bioscience, announces that the company presents the status of the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer.

Polyneuron Pharmaceuticals AG announced that regulatory authorities in France, the Netherlands and the UK have approved the clinical trial application for a phase I/IIa study of PN‑1007 for the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system.

Calliditas Therapeutics AB provided an update on its business activities and financial position as well as the initiatives announced to continue to build its organization amid the evolving COVID-19 pandemic, all while promoting the continuity of the development of its late stage R&D portfolio.